Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease

Launched by RENJI HOSPITAL · Mar 27, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how two types of medications, called SGLT2 inhibitors and GLP-1 receptor agonists, can help obese patients with kidney disease. The main goal is to see how these treatments affect kidney function and the amount of protein in urine over a 24-hour period. Patients who join the trial will be divided into four groups: one will continue their current medication, while the others will receive either SGLT2 inhibitors, GLP-1 receptor agonists, or a combination of both along with their existing treatment.

To be eligible for this trial, participants need to be between 18 and 75 years old, have a body mass index (BMI) indicating obesity, and have kidney disease confirmed by a recent biopsy. They should also have been on optimized treatment for their kidney condition for at least three months. This trial is currently recruiting participants, and those who join can expect regular check-ups to monitor their health and how well the medications are working. It's important to know that certain health conditions and medications may exclude someone from participating, so potential participants should discuss their individual situations with their healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Agree to join this study and sign an informed consent form;
• • 2. Age ≥ 18 years old and\<75 years old;
• • 3. BMI ≥ 25kg/m ² Or waist circumference ≥ 85cm (male)/≥ 80cm (female) or waist to hip ratio ≥ 0.9 (male)/≥ 0.85 (female);
• • 4. Confirmed obesity related kidney disease through renal biopsy within six months;
• • 5. Have received optimized treatment with RAS blockers and/or MRA for at least 3 months;
• Exclusion Criteria:
• • 1. Diagnosed as secondary obesity, such as hypothyroidism, Cushing's syndrome, polycystic ovary syndrome, etc;
• • 2. Severe renal insufficiency (renal function eGFR\<25 ml/min/1.73m2);
• • 3. There is acute kidney injury; Defined as: (1) An increase in blood creatinine of ≥ 26.5 within 48 hours μ Mol/L; (2) Within 7 days, the increase in blood creatinine exceeds 1.5 times the baseline value or more; (3) Reduced urine output (\<0.5 ml/kg/h) and lasting for more than 6 hours.
• • 4. Symptoms of active reproductive and urinary system infections
• • 5. Severe liver dysfunction (ALT/AST greater than 2.5 times the upper normal limit);
• • 6. Severe cardiovascular and cerebrovascular diseases, rheumatic and immune diseases;
• • 7. Serious metabolic diseases, such as diabetes ketoacidosis, hypertonic hyperglycemia, etc;
• • 8. Late stage malignant tumors;
• • 9. Have a known history of using drugs that affect glucose and lipid metabolism, such as glucocorticoids, antibiotics, anti anxiety or antidepressants, etc;
• • 10. Severe bleeding tendency and inability to complete venous blood collection;
• • 11. There are contraindications for MRI examination, such as patients with pacemakers, nerve stimulators, artificial metal heart valves, etc; Patients with claustrophobia; Epilepsy patients, etc.
• • 12. Pregnant/lactating women;